Complement Pharma, focused on complement inhibition to modify neurodegenerative disease progression.

 
  • bomen-home

First Therapeutic Product Focus

Complement Pharma is developing a line of products based on proprietary monoclonal antibodies to inhibit formation of the Membrane Attack Complex (MAC) part of the complement pathway.

Complement Pharma is developing new therapies for neurodegenerative indications.

About us

Complement Pharma is a biotech company focusing on complement inhibition to modify neurodegenerative disease progression. The Company was founded in 2017 to translate the opportunities of complement (C6) inhibition into clinical products for patients.

Posts

3rd Annual Complement-based Drug Development Summit 2019, November 13-15, 2019 Boston, MA

17th European Meeting On Complement in Human Disease, EMCHD 2019, Madrid, September 14 - 17, 2019

Bio-Europe Spring 2019, March 25-27, Vienna